Virax Biolabs Group Limited (NASDAQ)
Key Finding: Virax Biolabs (VRAX) is a micro-cap UK-based biotech developing T-cell immune profiling diagnostics primarily for post-acute infection syndromes such as Long COVID, which experienced extreme volatility and a multi-hundred percent surge in July 2026 following a Southeast Asia distribution deal and funding announcements.
Fact: Virax Biolabs Group Limited is a biotechnology company focused on immune response detection, T-cell immune profiling, and in vitro diagnostic technologies for viral and immune-mediated diseases.1
Key Focus Areas:
| Metric | Value | Source/Notes |
|---|---|---|
| Employees | 26 | Company filings |
| CEO / Co-Founder | James Foster | Multiple sources |
| Fiscal Year End | March 31 | Yahoo Finance |
| Website | viraxbiolabs.com | Official |
Interpretation: The company's primary value driver appears to be the clinical development of ViraxImmune, with potential revenue from research reagents in the near term.
Uncertainty: Detailed pre-2021 operational history is limited in public sources; early activities appear centered on distribution of diagnostic kits and PPE before shifting emphasis to proprietary T-cell technologies.
Fact: As of close on July 9, 2026: $6.36 (+100.00% from previous close of $3.18). Market cap approximately $5.07 million. 52-week range: $2.50 – $28.50.
| Period | Performance | Notes |
|---|---|---|
| 1 Day | +100% | News-driven surge |
| YTD | +26.47% | Yahoo Finance data |
| 1 Year | Highly volatile (~ -85% pre-surge) | Pre-reverse split adjusted |
| All-time | Extreme swings (pre-split highs >$7,000) | Multiple reverse splits |
Links for more information:
Uncertainty & Limitations: Historical price data is heavily impacted by multiple reverse stock splits (most recent 1:25). Low float and micro-cap status make the stock highly susceptible to momentum trading and news-driven volatility. Revenue remains minimal (~$12k TTM); profitability negative.
| Metric | Value | Notes |
|---|---|---|
| Revenue (TTM) | $12,420 | Fact from filings |
| Net Income (TTM) | -$5.02 million | Fact |
| EPS (TTM) | -$12.64 | Adjusted post-split |
| Cash Position | ~$6.5 million | Low debt |
| Market Cap | ~$5.07 million | Post-surge |